Kiniksa Pharmaceuticals International (KNSA) Times Interest Earned (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) posted Times Interest Earned of $43.04 for Q1 2026, down 99.78% on a QoQ basis from $19768.0 in Q4 2025, and down 99.03% year-over-year from $4424.0 in Q1 2025.
Kiniksa Pharmaceuticals International (KNSA) Times Interest Earned (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International's Times Interest Earned history runs 10 years deep, the most recent figure standing at $43.04 for Q1 2026.
- Quarterly Times Interest Earned fell 99.03% year-over-year to $43.04 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.08 (up 102.6% YoY) and the FY2025 annual result came in at $0.36, up 621.22% from the prior year.
- Times Interest Earned was $43.04 for Q1 2026 at Kiniksa Pharmaceuticals International, down from $19768.0 in the prior quarter.
- Across five years, Times Interest Earned topped out at $19768.0 in Q4 2025 and bottomed at -$4829.0 in Q3 2024.
- A 5-year average of $1862.2 and a median of $0.16 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned sank 130446.96% — and 2025, when it surged 6384982.7%.
- Kiniksa Pharmaceuticals International's Times Interest Earned stood at $0.31 in 2022, then sank by 99.52% to $0.0 in 2023, then sank by 20990.02% to -$0.31 in 2024, then jumped by 6384982.7% to $19768.0 in 2025, then tumbled by 99.78% to $43.04 in 2026.
- Business Quant data shows KNSA's Times Interest Earned at $43.04 in Q1 2026, $19768.0 in Q4 2025, and $2183.7 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Kiniksa Pharmaceuticals International | 4.82 Bn | 4.36 Bn | 193.47 Mn | 43.04 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.04 |
| Dec 31, 2025 | 19,768.00 |
| Sep 30, 2025 | 2,183.73 |
| Jun 30, 2025 | 775.38 |
| Mar 31, 2025 | 4,424.00 |
| Dec 31, 2024 | -0.31 |
| Sep 30, 2024 | -4,829.00 |
| Jun 30, 2024 | -14.63 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | -3.70 |
| Jun 30, 2023 | -0.20 |
| Dec 31, 2022 | 0.31 |
| Dec 31, 2021 | -0.28 |
| Sep 30, 2021 | -2.15 |
| Jun 30, 2021 | -2.85 |
| Mar 31, 2021 | -3.46 |
| Dec 31, 2020 | -5.68 |
| Sep 30, 2020 | -27.13 |
| Jun 30, 2020 | -16.92 |
| Mar 31, 2020 | -5.43 |